Ramosetron

	WikiDoc Resources for Ramosetron
Articles
Most recent articles on Ramosetron Most cited articles on Ramosetron Review articles on Ramosetron Articles on Ramosetron in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Ramosetron Images of Ramosetron Photos of Ramosetron Podcasts & MP3s on Ramosetron Videos on Ramosetron
Evidence Based Medicine
Cochrane Collaboration on Ramosetron Bandolier on Ramosetron TRIP on Ramosetron
Clinical Trials
Ongoing Trials on Ramosetron at Clinical Trials.gov Trial results on Ramosetron Clinical Trials on Ramosetron at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Ramosetron NICE Guidance on Ramosetron NHS PRODIGY Guidance FDA on Ramosetron CDC on Ramosetron
Books
Books on Ramosetron
News
Ramosetron in the news Be alerted to news on Ramosetron News trends on Ramosetron
Commentary
Blogs on Ramosetron
Definitions
Definitions of Ramosetron
Patient Resources / Community
Patient resources on Ramosetron Discussion groups on Ramosetron Patient Handouts on Ramosetron Directions to Hospitals Treating Ramosetron Risk calculators and risk factors for Ramosetron
Healthcare Provider Resources
Symptoms of Ramosetron Causes & Risk Factors for Ramosetron Diagnostic studies for Ramosetron Treatment of Ramosetron
Continuing Medical Education (CME)
CME Programs on Ramosetron
International
Ramosetron en Espanol Ramosetron en Francais
Business
Ramosetron in the Marketplace Patents on Ramosetron
Experimental / Informatics
List of terms related to Ramosetron

Ramosetron
	File:Ramosetron.svg
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	Intravenous
ATC code	none;
Pharmacokinetic data
Elimination half-life	5.8 hours
Identifiers
	IUPAC name (1-methyl-1H-indol-3-yl)[(5R)-4,5,6,7-tetrahydro-1H-benzimidazol-5-yl]methanone;
CAS Number	132907-72-3 ;
PubChem CID	108000;
IUPHAR/BPS	2301;
UNII	7ZRO0SC54Y;
ChEMBL	ChEMBL1643895 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C17H17N3O
Molar mass	279.33 g/mol
(what is this?) (verify)

Overview

Ramosetron (INN) is a serotonin 5-HT₃ receptor antagonist for the treatment of nausea and vomiting.^[1] Ramosetron is also indicated for a treatment of “diarrhea-predominant irritable bowel syndrome in males”.^[2] In India it is marketed under the brand name of "IBset".

It is only licensed for use in Japan and selected Southeast Asian countries. It is commonly sold under the tradename Nasea and in India as Nozia (300 mcg/ml Inj. & 100 mcg Tab.) ^[3]

References

↑ Fujii Y, Saitoh Y, Tanaka H, Toyooka H (2000). "Ramosetron for preventing postoperative nausea and vomiting in women undergoing gynecological surgery". Anesth. Analg. 90 (2): 472–5. doi:10.1097/00000539-200002000-00043. PMID 10648342. Unknown parameter |month= ignored (help)
↑ http://www.astellas.com/en/corporate/news/detail/astellas-launches-irribow-for.html
↑ Abriged prescribing information - Nasea (MIMS Philippines). Retrieved on June 13, 2008.

Template:5-HT3 antagonists

[1] Fujii Y, Saitoh Y, Tanaka H, Toyooka H (2000). "Ramosetron for preventing postoperative nausea and vomiting in women undergoing gynecological surgery". Anesth. Analg. 90 (2): 472–5. doi:10.1097/00000539-200002000-00043. PMID 10648342. Unknown parameter |month= ignored (help)

[2] ttp://www.astellas.com/en/corporate/news/detail/astellas-launches-irribow-for.html

[3] Abriged prescribing information - Nasea (MIMS Philippines). Retrieved on June 13, 2008.

[1]

[2]

[3]

Ramosetron

Overview

References

Navigation menu